Elections

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

Namandje Bumpus' departure means there is no obvious, internal candidate to serve as acting commissioner when President-elect Donald Trump takes office in January and the Senate works to confirm a new leader.

“I think the Republican Congress is going to slow down all of what's called progress, for lack of a better word, toward having hemp be accessible to folks in all kinds of forms,” says Doug Gansler, former Maryland state AG and chair of Cadwalader, Wickersham & Taft LLP’s state AG practice.

Public Company Edition: President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the US Department of Health and Human Services is seen as raising the potential for regulatory risk. Also, Geron revealed up to $375m in royalty and debt financings, while Zai Lab grossed $200m in a FOPO.

The FDA's current leader, whose term will end with Donald Trump’s second inauguration, also described three qualities the agency’s next commissioner will need to succeed, including "believing that there is such a thing as expertise."

The FDA's current leader, whose term will end with Donald Trump’s second inauguration, also described three qualities the agency’s next commissioner will need to succeed, including "believing that there is such a thing as expertise."

Following Energy and Commerce Health Subcommittee hearing about FDA’s human food and tobacco programs on 10 September, gap between what the trade groups, committee leadership and the FDA each want more of doesn’t appear to be shrinking.

The US' approach to international trade and potential for new tariffs on China or other partners could be the most significant issue for the beauty industry ahead of the presidential election in November, experts suggested at the Independent Beauty Association’s Cosmetics Convergence Fall 2024 Symposium.

In addition to commentary and information about the OTC drug, dietary supplement and cosmetic industries, speakers offered candid remarks on subjects well known across the consumer health industry or well recognized by consumers.